Pharmacoeconomics in Practice



Pharmacoeconomics in Practice

May 27th, 2011

Sava Center, Belgrade, SERBIA

First International Conference of Pharmacoeconomics Section will take place in Belgrade, on May 27th, 2011, ( Pharmacoeconomics Section introduces this conference which will be of interest to all health care professionals who participate in processes of managing the system, subsystems and segments of health care, professionals from the Ministries of Health, Health technology assessors, Health insurers, professionals from Pharmaceutical industry (health economics & market access, marketing & sales departments), pharmacists from Hospital and Community pharmacies, respected doctors and key-opinion leaders, Patient Groups and Academia. The purpose of the Conference is to present examples of Pharmacoeconomics and Health Technology Assessment practices that resulted in proposals for improving health care, increasing efficiency, cost reduction and harmonization of regulations. In addition, participants will be able to improve their skills and knowledge in the area of pharmacoeconomics.

We look forward to welcoming you in person at PHARMACOECONOMICS SECTION OF PHARMACEUTICAL ASSOCIATION OF SERBIA First International Conference, 2011!

Program of the Conference is accredited by the decision of the Health Council of Serbia No. 153-02-575/2011-02 of 01/03/2011, (accreditation number B-121/11), as International course of the first category, for pharmacists and physicians, with 7 points for the participants and 13 points for lecturers.

Honorary Committee

Prof.dr Ivanka Miletić Prof. dr Darko Ivanović Prof. dr Nada Kovačević Prof. dr Ljiljana Tasić Prof.dr Ana Sabo

Scientific Committee

Tanja Novaković Danka Stefanović Krzysztof Landa Prof. dr Slobodan Janković

Organizing Committee

Dragana Sovtić Danka Tešić Dubravka Urošev Ivana Zarić

08.30-09.00 Registration

09.00-09.15 Opening ceremony

Professor Ivanka Miletić

President of Pharmaceutical Association of Serbia

MSc.Pharm Tanja Novaković

President of Pharmacoeconomics Section, Galenika a.d., Serbia

09.15–11.00 Panel 1. Reimbursement and pricing of drugs

Strategic management of pharmaceutical market

Luka Vončina, PhD

Head of Medicines and Medical Devices Department Croatian Institute for Health Insurance, Croatia

Reimbursement and Pricing of medicines in Hungary with overview on Eu countries

Danko David

Research leader Corvinus University of Budapest Institute of Management, Hungary

Selected European experience in drug pricing - what is applicable for Serbia?

Professor Slobodan Aćimović

Faculty of Economics, University of Belgrade, Serbia

11.00-11.30 Networking coffee break

11.30-13.00 Panel 2. Practices and perspectives in Health Technology Assessment

Ensuring high quality of economic studies in health care by HTA guidelines – their importance in a middle income country

Krzysztof Landa, M.D.

CEO of HTA Audit, Poland

HTA in Poland on the map of European achievements – actual changes

Magdalena Wladysiuk M.D.

Vice – president HTA Consulting, Poland

13.00-13.30 Guidelines for Pharmacoeconomic evaluation for Serbia

Tanja Novaković, MSc.Pharm, Galenika a.d., Serbia Danka Stefanović, MSc.Pharm, ADOC d.o.o., Serbia Danka Tešić, B.Pharm, Medicines and Medical Devices Agency of Serbia Goran Medić, MSc.Pharm, Mapi Values, Netherlands Dragana Sovtic, MSc.Pharm, Pharmaceutical Chamber of Serbia, Serbia

13.30-14.30 Lunch break

14.30-15.30 Short course 1. Economic evaluation of pharmacy services Rachel A Elliott B.Pharm PhD MRPharmS Lord Trent Professor of Medicines and Health Division for Social Research in Medicines and Health The School of Pharmacy, University of Nottingham
15.30-16.00 Networking coffe break
16.00-17.30 Short course 2. Pharmacoeconomic model in practice – basic course Goran Medić, MSc.Pharm Research Associate Mapi Values, Netherlands
17.30-18.00 Final test and Evaluation
18.00-18.15 Closing the Conference MSc.Pharm Tanja Novaković President of Pharmacoeconomics Section, Galenika a.d., Serbia

Luka Vončina

Luka Vončina, MD, MSc is head of Department for Drugs and Medical Products at the Croatian Institute for Health Insurance. Dr. Vončina is also member of the management board at Croatian Institute of Public Health and is actively involved in the management of several projects implemented by the Croatian Ministry of Health and Social Welfare: ePrescription in the framework of the Croatian National Primary Health Care IT System Project and the World Bank loan financed Development of Emergency Medical Services and Investment Planning Project. Dr. Vončina was educated in Medicine (University of Zagreb in 2002) and in International Health Policy (MSc degree from the London School of Economics in 2005). Dr.Vončina has authored over 20 publications, including scientific papers in international peer reviewed journals.

Strategic management of pharmaceutical market

Luka Vončina, Croatian Institute for Health Insurance

In 2009 and 2010 Croatia substantially reformed its pricing and reimbursement regulation for medicines. Main goals of the reform were to a) maximize value for tax payers’ money, b) raise the efficiency and transparency of high level decision making, and c) ensure ethical promotion practice. The results of the reform enabled the Croatian national health insurance fund (Croatian Institute for Health Insurance; HZZO) to generate extensive savings while at the same time improving access to innovative medicines. In the 18 month period from July 2009 to December 2010, as many as 64 innovative molecules were added to HZZO’s lists of reimbursed medicines and 13 innovative molecules to its list of expensive hospital medicines. For comparison, a total of 45 were listed in the period from 2002 to 2009. Comparing expenditure in the first 6 months of 2009 and 2010, HZZO’s expenditure on prescription medicines decreased by an additional 13% from 1.7 billion kn to 1.5 billion kn, while its expenditure for expensive hospital medicines decreased by 28,5% from 219 million kn to 157 million kn.

Dávid Dankó

Dávid Dankó is currently research leader at the Institute of Management of the Corvinus University of Budapest, where he lectures pharmaceutical and medical device reimbursement, health care management and strategic management. His research activities have recently been focused on the practical applicability of innovative reimbursement techniques, and the possibility of incentivizing patient adherence via the reimbursement system.

Having studied in Sweden and Germany, he received his MSc degree in Economics at Corvinus in 2003, and went on to pursue PhD research in the field of long-term resource management in the innovative pharmaceutical industry. He is currently co-editing a comprehensive textbook on pharmaceutical reimbursement.

Dávid Dankó is managing director of Ideas & Solutions, an advisory firm which works together with leading pharmaceutical and medical device manufacturers on market access and pricing & reimbursement strategies, portfolio and product lifecycle strategies, as well as risk-sharing agreements and disease management.

Reimbursement and pricing of medicines: a strategic approach and Hungarian experiences

Dávid Dankó, Corvinus University of Budapest

Reimbursement policy is currently emerging as a field on the border of health economics and public policy. Although it has a lot in common with pharmacoeconomics, it approaches the reimbursement and pricing of medicines from a somewhat different, strategic, system-level approach. The presentation highlights the differences of reimbursement policy and pharmacoeconomics, presents the goals of reimbursement policy, outlines how a sustainable reimbursement system should be set up, and points out the relationships between reimbursement policy and market access.

The presentation then demonstrates how we attempted to implement a strategic framework for pharmaceutical reimbursement in Hungary between 2007 and 2009, and what the results and limitations were. It can clearly be seen that for a country to establish a sustainable reimbursement system, a strategic, system-level approach is indispensable. We also look at the major European markets to identify signs and constraints of strategic thinking in pharmaceutical reimbursement.

Professor Slobodan Aćimović

Slobodan Aćimović, PhD is associate professor at the Faculty of Economics, University of Belgrade. University education gained at the Faculty of Economics, University of Belgrade: undergraduate studies (1993), graduate-master studies (1997), PhD thesis (2001). Professional career at the Faculty of Economics: demonstrator (1994.), assistant trainee (1995.), teaching assistant (1997), assistant professor (2002.) and associate professor (2007), within the department of business economics and management. Currently in charge of the following subjects: Marketing Logistics (undergraduate studies) and Supply Chain Managment (graduate studies).

Especially active in carrying out strategic and operative consulting activities in domestic and regional companies. Special activates in the role of coordinator/team member in a wide range of business economics and management projects in the following fields: establishment of adequate level of company offer (customer service), policy of supplies management, as a logistics-marketing strategy, different kinds of market research, analysis and improvement of company business strategy, improvement of macro and micro organisation, workplace systematisation, due dilligence, investment project analysis, business plan creation etc.

Selected European experiences in pricing of medicines

what is applicable in Serbia?

Professor Slobodan Aćimović, Faculty of Economics, University of Belgrade

Drug pricing policy in the most of countries (except the United States as a very liberal market) is regulated by government. The drug is a specific good, with derived and extremely inelastic demand (if prices rise, demand does not fall), therefore some kind of drug prices control is desirable. Rather, in most EU countries is still present financial control of total drug consumption by the state as monophony customer. Additional drug specificity is that the state pays for them, doctors select them, and patients use. The interests of these three groups should be properly balanced by state pricing regulations for medicines.

All over the world, pricing regulations for medicines are different, but all differences can be subsumed under two basic models of drugs pricing: 1) International reference pricing (in most European countries) and 2) Therapeutic reference pricing (Germany, Spain, Italy, France). Also, in most cases the level of producer price (wholesale price) is controlled, while in a small number of cases the reference level of purchase price is pharmacy. Generally, the relation between regulation and deregulation are changing in every country in the direction of faster or slower liberalization, but economic crisis (global or partial) could slow down or completely stop this trend.

Serbia is one of the countries with reference control of all drug prices. Since the introduction of clear rules (law, regulations and decisions on Drugs from 2004) to the present regulation of drugs is gradually weakening, the OTC segment was last year acquitted of regulations, parities of many Rx drugs have been corrected, etc However, changes that lead to liberalization, as a general European trend of drug prices are still slow and rather limited by scarce state funding. It all implies some negative tendencies in Serbian pharmaceutical market, such as permanent quantitative and financial growth in drug consumption (which is very strange trend in spite of still strong regulation), extreme domination of generic drugs, the appearance of corruption (which always accompanied by a high degree of regulation) in different procedures related to drugs and so on.

Paper provides the bases of guidelines for future changes in the Serbian policy of regulating drugs, which could be implemented on the basis of comparable European practice. Additional liberalization of drug pricing and procedures for changing drug prices will presumably be some sort of prerequisite for further progress of Serbia towards EU membership. However, any further step in the liberalization of the definition of drug prices may bring benefits primarily to patients (treated with better drugs), pharmaceutical companies (which will increase sales), but also to a state that will increase budget for health by its adequate allocation work on the good for the whole nation.

Krzysztof Landa

The CEO of HTA Audit, a company dealing with quality of HTA reports directed to authorities and public institutions in Poland; the President of Watch Health Care Foundation (www.; former President of the Central & Eastern European Society of Technology Assessment in Health Care ( In 2006-2007 Dr Landa was the Director of Drug Policy Department in the Central Office of National Health Fund. In 2004 Krzysztof Landa was elected to the Board of Directors of Health Technology Assessment International (HTAi) and performed his duties till mid 2007. He was the Chairman of the LOC of the first HTAi Annual Meeting 2004, held in Krakow, Poland.

Dr. Landa is a graduate of the University School of Medicine and received his management education at the Postgraduate School of Public Health of Jagiellonian University in Krakow. In 1997-98 Dr. Landa worked for the Harvard-Jagiellonian Consortium for Health in Krakow. From 1998 to 2002 he directed the Bureau for the Standardisation of Medical Practice of the National Center for Quality Assessment in Health Care (NCQA), a governmental institution.

Promotion of HTA in the region of CEE resulted in international cooperation in education and HTA. Dr. Landa organized many national and international HTA workshops and conferences. In years 2006-2008 Dr. Landa provided consultancy for the Serbian Ministry of Health. He was team leader of the World Bank project aimed at introduction of HTA in Serbia, implementation of EBHC principles to the management of basic benefit package and designing a governmental HTA Agency.

Ensuring high quality of economic studies in health care by HTA Guidelines – their importance in a middle income country

Krzysztof Landa, HTA Audit

Polish Ministry of Health established AHTAPol in 2005 in light model (reactive agency) as an advisory body to support decision-making. In 2007 HTA guidelines (clear quality requirements) were published and the Consultative Council which includes external experts (eg, from the National Health Fund, Supreme Medical Council, and Medical Universities Rectors Conference) was created. In 2009 HTA Agency in Poland (AOTM) was established by law and HTA guidelines were updated. The purpose of these guidelines is to indicate the principles and basic methods of Health Technology Assessment to ensure high quality of analyses and reliable results.

To fulfill demand of HTA reports with adequate supply, it is less costly for the society to introduce a light HTA Agency. Therefore it is much easier to adequately address demand by supply of HTA reports and further, desired status of EBHC by the countries with light HTA Agencies than those with heavy HTA. Heavy HTA Agencies must hire many more highly specialized employees to properly address demand of valid information in a system or they do not perform efficiently.

A light-heavy dimension in describing an HTA Agency is rather a theoretical one. It allows for managerial considerations before HTA Agency has been rooted in a health care system or allowing for modifications in performance of such Agency. Only few HTA Agencies are strictly light and only few are totally heavy. Usually there is a mixture of light and heavy features

In Polish Guidelines there are three strategies of conducting economic analysis of health technology are foreseen:

  1. There is a relevant economic analysis examining a decision-related problem in question. It is possible to use the model on which the analysis was based as well as clinical data. The analytical task consists in taking into account Polish data concerning the use of resources and costs.
  2. There is a recent and valid cost-effectiveness analysis (systematic review) made abroad or in Poland. The analytical task consists in performing an economic analysis based on the data from this analysis or on modeling using those data.
  3. Conducting both, cost-effectiveness analysis and the economic analysis de novo. After having defined the cost effectiveness by means of the systematic review, clinical efficacy, the gathered data are used in the economical analysis

Magdalena Wladysiuk

Magdalena is Vice president at HTA Consulting. She is a medical doctor with MBA in Technology Management. In the Republic of Serbia, she was HTA Consultant at Technical Assistance for Health Technology Assessment. The aim of this project was to develop institutional capacity in the Ministry of Health and Health Insurance Fund and other health institutions and improve the Basic Benefits Package, the public / private mix of financing and delivery, the provider payment and contracting systems and tools, including monitoring and evaluation mechanisms, and to increase the equity of distribution of health resources across the Republic of Serbia.

Membership of Professional Associations:

Fellow Health Technology Assessment International (HTAi)

Fellow International Society of Pharmacoeconomisc and Outcome Research (ISPOR)

Fellow Central and Eastern European Society of Technology Assessment in Health Care


HTA in Poland on the map of European achievements – actual changes

Magdalena Wladysiuk, HTA Consulting

In 2009 HTA Agency in Poland (AHTAPol) was finally established by new law “Basket Law” with all regulations of application processes, obligations of pharmaceutical companies. In Polish Parliament it is new law in preparation “Reimbursement Law” which probably will change dramatically pricing and reimbursement system.

The main reason to create Reimbursement Law was idea to regulate the drug market in one document (in this moment 4 Laws are involved) and implemented all obligations from Transparency Directive.

The main changes included in the new Law:

General payback above total budget for open care drugs in 50% to 50% share,

Fix prices and fixed margin for wholesalers and pharmacists,

New criteria calculation of copayment level for patients,

New type of therapeutic groups and new way of calculations of reference pricing

limiting them.

Obligation of HTA reports for all drug parts of basic benefit packages,

Implementation of risk sharing schemes.

The changes in reimbursement system are mainly focused on cost containment regime and address more demand to pharmaceutical companies. The role of HTA reports and HTA Agency are even more strengthened then before. HTA data will be used as first step to receive strong recommendation from HTA Agency. The assessment will be focused not only on clinical part. To receive reimbursement it is necessary to have ICER below threshold (3 X GDP per QALY). Also risk sharing scheme will be assess in this process and it means that data from HTA reports must be linked with RSS. The essential in system to start collecting Polish data about diseases, states of patients and real cost of illness. The data could be used in cost-effectiveness analyses and especially in budget impact analyses, which could be introduced for risk sharing proposition.

Tanja Novaković, MSc.Pharm

Tanja Novaković, MSc Pharm is Product manager for drugs for Central nervous system in Galenika a.d., Serbia. Since 2006 she is president of Pharmacoecomics Section within Pharmaceutical Association of Serbia and from 2007 to 2009 vice president of ISPOR Serbia chapter. In 2005 she finished postgraduate studies at Faculty of Pharmacy at Ghent University in Belgium. She is author of the first publication in Serbian language in field of pharmacoeconomics “Handbook for pharmacoeconomic evaluations”. She is also author of first guidelines for pharmacoeconomic evaluations for Serbia. Participated in Health Technology Assessment projects of Serbian Ministry of Health and supported by World Bank and Project in Health Diplomacy of DiploFoundation and Swiss Agency for Development and Cooperation. She is member of managing board of Pharmaceutical Association of Serbia, founder of ISPOR Serbia and member of ISPOR.

Danka Tešić, B.Pharm

Danka is employed at Medicines and Medical Devices Agency of Serbia. Her present position is Senior Associate in Licensing Department. Scientific Field of Expertise: Doctoral Academic Studies, Clinical and experimental pharmacology, Medical faculty in Kragujevac and Pharmacoecnomics. Current Participation in Science Projects: Guideline for pharmacoeconomics analysis for Serbia and professional skills upgrades are: ISPOR Serbia courses, ISPOR courses, HTA course and courses organized by Faculty of Pharmacy, University of Belgrade. Membership in Professional Associations: International Society of Pharmacoeconomics and Outcome Research (ISPOR), Pharmaceutical Society of Serbia, Pharmacoeconomic Section.

Danka Stefanović, MSc.Pharm

Danka is employed at ADOC Pharmaceuticals. Her present position is Health Economics Manager. Scientific Field of Expertise: Doctoral Academic Studies, Pharmacology, Faculty of Pharmacy, University of Belgrade and Pharmacoecnomics. Current Participation in Science Projects: Guideline for pharmacoeconomics analysis for Serbia. Professional skills upgrades are: ‘Improvement of Health in Serbia’ and its part: Health Technology Assessment. The name of the paper was: ‘Efficacy, safety and cost-effectiveness analysis of peginterferon alfa vs. interferon alfa both combined with ribavirin in treatment of chronic hepatitis C’, (from 2006-2007). She has finished six weeks course “International Health Economic” at the Centre for Health Economics, University of York, UK. Membership: Pharmaceutical Society of Serbia, Executive Board, Pharmacoeconomics Section, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), founding member of the ISPOR Chapter Serbia.

Dragana Sovtić, MSc.Pharm

Dragana is employed at Pharmaceutical Chamber of Serbia. Her present position is Indipendent advisor for pharmaceutical issues. Scientific Field of Expertise: Pharmacoecnomics, pharmaceutical legislation. Current Participation in Science Projects: Guideline for pharmacoeconomic analysis for Serbia. Professional skills upgrades are: ISPOR Serbia courses, ISPOR courses, World Bank workshops, Courses organized by Faculty of Pharmacy, University of Belgrade. Membership in Professional Associations: International Society of Pharmacoeconomics and Outcome Research (ISPOR), Pharmaceutical Society of Serbia, Pharmacoeconomic Section, vice president of the Pharmacoeconomic Section since 2006.

Guidelines for Pharmacoeconomic evaluation for Serbia

Tanja Novaković, Danka Tešić, Danka Stefanović, Goran Medić, Dragana Sovtić

Facing rising costs for medicines, national health insurance funds all over the world are looking for a way to prioritize the allocation of available resources to ensure the highest possible level of health to the population they serve. Pharmaco-economists had long argued that all decisions about the use of public funds should be based on careful evaluation of both the effects of intervention and on its costs, in order to choose between competitive therapeutic options. Economic evaluations are tools that health economists use to assess effectiveness of therapeutic interventions.

The need for the first guidelines for pharmacoeconomic evaluation in Serbia emerged as a result of permanent changes in the Serbian health system and in the world.

The guidelines were written in accordance with best European and international guidelines, with respect to the existing legislation in Serbia. It is based on a “reference case” which includes set of preferred methods which analysts should follow when conducting pharmacoeconomic evaluations and the essential elements for each economic evaluation. The purpose of the reference case is to aid decision making by enhancing the consistency by which economic evaluations are conducted and reported, thereby improving the comparability among evaluations.

The guidelines are primarily intended for those who conduct pharmacoeconomic studies, Serbian decision makers and policy makers who are responsible for funding decisions regarding medicines (professionals from the Republic Institute for Health Insurance, from Ministry of Health, Health technology assessors). In addition, guidelines are intended for academics, scientific researchers in the field of pharmacoeconomics, health care professionals and associates who participate in the processes of managing the systems, subsystems, segments of health care, experts from the pharmaceutical industry (health economics & market access, marketing & sales departments), pharmacists from hospital and public pharmacies, patient groups, as well as those who are interested in the field of pharmacoeconomics.

Rachel Elliott

Rachel Elliott is a UK qualified pharmacist with a background in critical care, has a PhD in health economics and her research perspective is in health economics and health technology assessment, focussing on the economic analysis of medicines in real-world settings. She is head of the Division of Social Research in Medicines and Health, at the University of Nottingham School of Pharmacy. The principal research themes of her research group are in the economics of medicines nonadherence, influencing medicines taking behaviour, medicines quality and safety in children, young people and the elderly, pharmaceutical policy and infections. She is a member of the NICE appraisal committee, and a member of the Health Services Research Network (HSRN) Executive Board.

Are pharmaceutical services an efficient use of health care resources?

Rachel Elliott, University of Nottingham

Many countries strive to ensure that medicines are safe and used appropriately to maximise health gain. Cost-effective use is also a mandate of governments looking for efficiency in the allocation of scarce resources.

Pharmacists can optimise medicines-related health care provision, through physician education, prescribing guideline development and implementation, reduction in medication prescribing and monitoring errors, and better support for patients to enhance their medicines adherence. However, in a resource-constrained environment, pharmacists need to demonstrate that any increased costs associated with their services can lead either to better patient outcomes, reduced overall costs, or both.

Recent economic evaluations suggest that interventions involving pharmacists (such as treatment of cardiac risk in patients with Type 2 diabetes, or adherence-enhancing interventions) are cost effective. However, other studies suggest that pharmacists do not improve outcome, and increase costs. In fact, a recent systematic review of over 100 economic evaluations of pharmacy services reported that pharmacist-provided care was favorable in only 16% of studies. Most were limited by their partial cost analyses, study design, had serious limitations in their methodological quality and applicability to current practice, did not use a comparative study design or include incremental cost-effectiveness analysis. Poor quality of economic studies of pharmacy services may reduce uptake of services. Therefore it is essential that better quality studies are carried out in future, and the pharmacy profession is involved in initiating economic evaluations of pharmaceutical services so that pharmacists direct the use of health economics to prove the value of their profession.

Goran Medić

Goran Medić, MSc.Pharm, is Research Associate for Mapi Values in the Netherlands. His role involves performing systematic literature reviews, meta-analysis, writing reimbursement and health economic dossiers, developing and adapting health economic models for reimbursement and international marketing.

Prior to joining Mapi Values, Goran worked as Health Economics and Reimbursement Coordinator EMEA (Europe, Middle East, and Africa) for KCI Europe Holding in the Netherlands. He was responsible for writing HTA responses, coding applications, KOL management, and building Budget Impact Models.

He finished Master of Pharmacy at the University of Belgrade, Faculty of Pharmacy, Serbia. After earning his Masters of Pharmacy degree (2004), he specialized in Pharmacoeconomics and Pharmaceutical Legislation (2005).

Pharmacoeconomic models in practice – basic level

Goran Medić, Mapi Values

This is a basic course focusing specifically on pharmacoeconomic modeling and intended for people currently undertaking modeling for pharmacoeconomic evaluation within the pharmaceutical and medical device industries, consultancy, and academia or for those reviewing or preparing economic evaluation evidence for public health authorities

The purpose of the course will be to demonstrate and show how to build pharmacoeconomic models step-by-step. Based on a case study (which will be provided) the basic “generic” model will be built. Practical things will be demonstrated in Excel, so it is recommended that participants bring their own laptops. The following things will be demonstrated: the structure of the model, layout in Excel, moving through the model, multiple selections of drugs/treatments, limiting input parameters, etc.

Golden sponsor

Silver sponsors

Bronze sponsor


Media partners

Sesija SFE SFUS - VII Kongres farmaceuta Srbije
Petak 12.10. 2018./ Hotel Crowne Plaza , Beograd, Srbija
Preliminarni program

VI međunarodna SFE SFUS konferencija
2. jun 2017. godine, Beograd, hotel Metropol, Srbija.

Sekcija za farmakoekonomiju Saveza farmaceutskih udruženja Srbije (SFE SFUS) organizuje Šestu međunarodnu konferenciju sa temom:

Peta međunarodna konferencija - Predavači
9. i 10. oktobar 2015. godine Beograd, hotel Metropol
dr sc. Brian Godman, Institut za farmaciju i biomedicinske nauke Strathclyde, Glazgov, Velika Britanija, Karolinska Institut, Švedska

dr sc. Wija Oortwijn, partner, ECORYS NL Roterdam, Holandija

dr Krzysztof Landa, predsednik, MedInvest Scanner Ltd M.I.S, Poljska

mr sc. Mark Parker, Odsek za zdravstvenu ekonomiju, Fakultet za menadžment, Univerzitet u Liverpulu, Velika Britanija

mr sc. Angela Yu, istraživač Fakulteta za ekonomiju i političke nauke u Londonu, Velika Britanija

Timothy Johnston, lider programa za rast i ljudski razvoj, Jugoistočna Evropa, Evropa i centralna Azija, Svetska banka

dr sc. Dávid Dankó, direktor, Ideas & Solutions, Mađarska

dr Günter Harms, direktor za pristup tržištu i odnose sa javnošcu, Shire, Nemačka

mr sc. Vanesa Benković, konsultant za procenu zdravstvenih tehnologija i istraživanja u zdravstvu, Hrvatska

dr Bojan Trkulja, direktor, INOVIA, Srbija

mr sc. Tanja Novaković, predsednica Sekcije za farmakoekonomiju SFUS, Srbija

mr sc. Jovan Mihajlović, Institut za farmakoepidemiologiju i farmakoekonomiju, Odsek za farmaciju Univerziteta u Groningenu, Holandija

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institut, Poljska

Alan Haycox, Odsek za zdravstvenu ekonomiju, Fakultet za menažment, Univerzitet u Liverpulu, Velika Britanija

Norbert Wilk, Arcana Institut, Poljska

Neven Lovrinov, Terimanl d.o.o., Hrvatska

Beograd, 28. april 2015. godina, hotel Crowne Plaza
Sekcija za farmakoekonomiju Saveza farmaceutskih Udruženja Srbije
Ciljevi konferencije su:
· Upoznavanje sa specifičnostima biofarmacetskih lekova i biosimilara,

· razumevanje regulative biofarmaceutskih i biološki sličnih lekova,

· predstavljanje kliničkog iskustva sa biološkim lekovima i uopšte,

· razmena iskustava i znanja sa stručnjacima iz regiona I Evrope.
Regulisano uvođenje novih lekova
11-13, maj 2015. godina, Varšava, Pojska
PIPERSKA grupa i Agency za HTA & Tarifni Sistem u Poljskoj i Svetska ždravstvena organižacija, Evropa
Kurs je prvenstveno namenjen zdravstenim stručnjacima koji se bave unapređenjem racionalnom upotrebom lekova posebno novih lekova.
Peti jadranski i Četvrti hrvatski kongres farmakoekonomike i istraživanja ishoda liječenja
Šibenik, Hrvatske, 23. do 26. april 2015. godine
Sekcija za farmakoekonomiku i istraživanje ishoda liječenja Hrvatskog društva za kliničku farmakologiju i terapiju Hrvatskog liječničkog zbora
Teme koje će na predstojećem kongresu biti u posebnom fokusu su: 'Uloga i značaj farmaceutske industrije na cjelokupno gospodarstvo država u regiji' te 'Potreba adaptacije modela za procjenu zdravstvenih tehnologija u državama s visokim rizikom održivosti financiranja zdravstvenih sustava u svrhu očuvanja transparentnosti i konkurentnosti'.
Registri pacijenata u cilju poboljšanja kvaliteta zdravstvene zaštite i smanjenja troškova lečenja
5. februara 2015. godine, hotel Crowne Plaza, Beogradu u 13.00 h
Sekcije za farmakoekonomiju Saveza farmaceutskih Udruženja Srbije (SFUS)
Ciljevi konferencije su:
• Upoznavanje i predstavljanje značaja i vrednosti registara pacijenata
• Upoznavanje sa zdravstenim ishodima terapija i ishodima prijavljenim od strane pacijenata
• Razmena iskustava sa zemljama koje imaju iskustva sa primenom registara pacijenata u
korišćenju podataka za farmakoekonomske analize
• Upoznavanje sa primerima specijalnih ugovora (Risk sharing, Pay per Performance)
Procena zdravstvenih tehnologija za obezbeđenje kvaliteta zdravstvene zaštite
15-16. decembar 2014.,Krakov, Poljska
IX Međunarodni Simpozijum CEESTAHC